Abstract:Renal transplant patients die prematurely of cardiovascular disease and LV hypertrophy is now recognised as an important adverse prognostic indicator. This study investigated the factors implicated in the development of echocardiographic abnormalities (including LV hypertrophy) and the possible differential effects of treatment with cyclosporin and azathioprine. A cross-sectional study was undertaken in 46 patients randomly assigned to immunosuppressant treatment with either cyclosporin or azathioprine at 1 year post-transplantation: patients were studied not less than 5 years after assignment to cyclosporin (CyA) - or azathioprine (Aza)-based treatment regimens. Although clinic blood pressure control was not different in the two treatment groups, 24 hour ambulatory BP (ABP), particularly night-time BP, was significantly higher in the CyA group. There was a trend for both left ventricular hypertrophy (61 vs. 43%) and carotid wall thickening (43 vs. 26%) to be more common in the CyA group though this failed to achieve statistical significance. Left ventricular mass was determined by ABP, rather than clinic BP, and was also associated with increased QT dispersion. Multivariate analysis identified that 24 hour ambulatory systolic blood pressure (ASBP) and time on renal replacement therapy (RRT) were the major determinants of LV mass. Thus, despite the absence of differences in clinic BP measurements, CyA treatment was associated with higher rates of cardiovascular functional and structural abnormalities. This small scale study has identified cardiovascular functional and structural abnormalities in renal transplant patients, particularly in those receiving CyA-based immunosuppressive therapy. However, rather than reflecting a direct effect of CyA they are related to increased 24 ABP (but not clinic BP). These data suggest that ABP should be used to monitor and target antihypertensive therapy in this high risk patient group. Moreover, the future use of non-calcineurin inhibitor immunosuppressant therapy may have benefits on blood pressure control and LV mass.

Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Early renal graft failure due to recurrence of Wegener's granulomatosis under cyclosporine therapy

Chronic injury of human renal microvessels with low-dose cyclosporine therapy

Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein

Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury

Long‐term results of cyclosporine‐steroid therapy in 131 non‐matched cadaveric renal transplants

The effect of cyclosporine on prognostic factors in cadaveric renal retransplantation

Resolution of papilledema associated with cyclosporine use after change to tacrolimus

Cyclosporine pharmacokinetics in diabetic patients after kidney and pancreas transplantation

Cyclosporine's immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation

Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels

Statin-induced Rhabdomyolysis in Renal Transplant Recipients: Two Cases Reports

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report

Cyclosporin A does not cause hyperlipidemia in kidney graft recipients

Rhabdomyolysis and acute kidney injury potentiated by a drug-drug interaction between cyclosporine, leflunomide, and rosuvastatin in a kidney transplant recipient: A missed opportunity for pharmacist involvement

Long‐term experience in primary cadaver renal transplants using cyclosporine

Cardiac and vascular abnormalities in renal transplant patients: differential effects of cyclosporin and azathioprine

Late-onset cytomegalovirus cholangiopathy in a renal transplant patient: Case report and review of the literature